We are building a deep pipeline of potentially differentiated therapies, with the goal of advancing care and outcomes for patients with diverse inflammatory diseases
- Preclinical
- Phase I
- Phase II
- Phase III
Antibody targeting IL-4Rα cytokine receptor
(Th2 cell modulator)
- Preclin
- Ph 1
- Ph 2
- Ph 3
Atopic Dermatitis (AD)
Atopic Dermatitis (AD)
Asthma
Asthma
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Chronic Rhinosinusitis with
Nasal Polyps (CRSwNP)
Small molecule targeting S1P1
(Th1 cell modulator)
- Preclin
- Ph 1
- Ph 2
- Ph 3
Ulcerative Colitis (UC)
Ulcerative Colitis (UC)
Crohn's Disease (CD)*
Crohn's Disease (CD)*
Peripherally restricted
H3 receptor antagonist
- Preclin
- Ph 1
- Ph 2
- Ph 3
Pruritus Associated with AD
Pruritus Assoc.
with AD
Antibody targeting IL-33
- Preclin
- Ph 1
- Ph 2
- Ph 3
Allergic Inflammation
Allergic
Inflammation
* Phase 2 Study ended early due to COVID-19-related enrolment challenges. New Phase 2 trial planned.
- Key:
- Ongoing
- Planned